BACKGROUND: Many patients with GBM only receive one line of therapy. GBM patients who cannot receive post-PD therapy are not easily identifiable at diagnosis and may represent up to 50% of patients (Graus, Neuro Oncol 2013; Chen, Asia Pac J Clin Oncol 2013). Since post-study treatment may confound OS analyses in clinical trials, we evaluated outcomes for AVAglio patients who did not receive post-PD therapy. METHODS: In AVAglio patients (n ¼ 921) received: BEV + RT/TMZ or placebo + RT/ TMZ (6wks); 28-day break; BEV + TMZ or placebo + TMZ (x6); BEV or placebo until PD/unacceptable toxicity. Co-primary endpoints: investigatorassessed PFS and OS. Post-PD therapy was received by 321 placebo (69%) and 284 BEV (62%) 
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